America’s future in medical innovation depends on what we build today. Across the country, biopharmaceutical companies are investing in the infrastructure, talent and technology that keep the U.S. at the forefront. We’re telling that story at 👇

August is National Immunization Awareness Month, a time to recognize the role vaccines play in protecting you, your family and our future. @mybarra breaks down 5 key things to know about vaccines—from how they work to why access & innovation matter. #NIAM.

Rural patients are losing out and urban hospitals cash in. A new study reveals how big-city hospitals exploit 340B by posing as rural providers. 🎭 Time to take off the mask.

Interested in a career in biopharma? PhRMA’s Virtual STEM Career Expo is back on September 30, 2025. Whether you're a student or early career professional, this event is a great way to learn more about the opportunities in our industry. Register for free.

PBMs and commercial insurers are routinely denying medicines prescribed by doctors. An @IQVIA_US study found that in 4 of 5 chronic disease areas:.-Over 90% of patients faced initial denials.-Delays averaged 3–5 weeks.-Some patients endured 11+ rejections before approval.

Since the 20th century, vaccines have helped drive down disease rates and turn once-deadly illnesses into largely preventable ones. Learn more about vaccine innovation and how vaccines are helping to build a healthier future for Americans. #NIAM.

A new study from @millimaninsight finds that patients face higher drug costs at 340B hospitals than at non-340B hospitals. If policymakers want to lower drug costs in the U.S., they must fix the 340B program.

The U.S. leads the world in developing, manufacturing and delivering innovative medicines, but other countries aren’t paying their fair share. Learn how we can balance the system while protecting innovation for patients across the globe:

The 340B program has no guardrails and as a result hospitals are abusing it at the expense of patients, taxpayers and employers. The rebate model is a commonsense tool that will help shield against program abuse.

Since 2014, the nation’s three largest PBMs have increased the average number of medicines excluded from many commercial health plans by 27% each year – that includes generics and biosimilars intended to drive patient savings. Learn more from a new study:

As more hospitals exploit the 340B program as a profit center, state and federal taxpayers face increased costs due to lost Medicaid rebates—hitting $6.5B in 2024. That’s a hidden tax on patients, taxpayers, and employers. It’s time to fix the 340B program. Read more from

We were proud to be a part of #NCSL2025, with PhRMA’s Katelin Lucariello joining a panel with state leaders to discuss how states are shaping the future of medicine. Learn more about the critical role states play in shaping the pharmaceutical landscape: 

🚨 New @modrnhealthcr piece highlights concern about how big, urban hospitals are using a loophole to qualify as “rural” and tap into drug discounts meant for providers treating underserved communities. Congress must fix the 340B program to stop the abuse and protect patients.

The U.S. leads the world in biopharma innovation. But staying ahead means investing in the next generation. Nicole Harriott from @neurocrine shares why nurturing young scientists is key to keeping America competitive.

Every American should have the option to protect themselves and their family with vaccines that are available and accessible. To kick off National Immunization Awareness Month, hear from PhRMA Chief Medical Officer, @mybarra, on why vaccines matter.

A new @IQVIA_US paper details how often PBMs and commercial insurers are blocking prescription access. - 3 in 4 patients were denied coverage for new prescriptions. - 67% never got their meds. PBMs & insurers are quietly blocking access—and patients are paying the price. It’s.

By demanding rebate pass-through, North Carolina is prioritizing transparency and accountability over opaque PBM practices that drive up costs for patients and the health system writ large. Their recent legislation can deliver meaningful relief to the people who need it most.

💡 New data shows how strong IP protections fuel U.S. innovation and power the biopharmaceutical sector, resulting in:. - 5M jobs.- 1,500+ production facilities in the U.S. - Innovative treatments and cures. Watch the video + read more:

Brain diseases like Alzheimer’s don’t just affect individuals. They also impact a patient’s family members and community. But innovative new medicines are beginning to change the trajectory of these diseases. Hear from Oskar Hansson at @EliLillyandCo about his commitment to

A @USCSchaeffer white paper reveals that the IRA doesn’t guarantee lower costs at the pharmacy. Why?. Because it does nothing to rein in insurers and PBMs who ultimately control what patients pay out-of-pocket.

Another major U.S. investment from @AstraZeneca!. PhRMA members continue to support patients, workers and communities across America.